Cannabis presentations to the emergency department after MVC in the era of legalization for recreational use

Alcohol and Drug Testing in Motor Vehicle Crashes

Alcohol-impairment is a leading cause of motor vehicle crash injuries and fatalities. It has also come to light in recent years that driving under the influence of drugs is becoming more and more prevalent and also contributes to motor vehicle crash injuries and fatalities. This review describes the effects of alcohol and commonly used drugs (hallucinogens,stimulants, etc) on driving capabilities, and the matrices and tests used to detect these analytes in motor vehicle drivers, pedestrians, and motorcycle drivers.

Drug interactions in a sample of inpatients diagnosed with cannabis use disorder

The majority of patients with cannabis use disorder (CUD) regularly take medication. Cannabinoids influence metabolism of some commonly prescribed drugs. However, little is known about the characteristics and frequency of potential cannabis-drug (CDIs) and drug-drug interactions (DDIs) in patients with CUD. Therefore, our study aimed to determine the prevalence and characteristics of drug interactions in patients with CUD during inpatient treatment on an addiction-specific ward over a six-year-period. To this aim, medication charts were analyzed and screened for potential CDIs and DDIs. Herein, the drugs.com classification for potential CDIs and UpToDate Lexicomp program for potential DDIs were utilized. The study cohort consisted of 301 patient cases, predominantly male (85.0%), with a median age of 37 years. 89.4% (269/301) of all cases involved were taking at least one drug that could potentially interact with cannabis. Levomethadone, buprenorphine and morphine were the most common drugs involved in potentially serious CDIs. In addition, 196 DDIs were identified, of which 25.5% were classified as 'avoid combination' and 74.5% as 'consider therapy modification'. Hereby, combinations of levomethadone with other psychotropic drugs most frequently accounted for potentially severe and mild DDIs. The results of our study indicate that especially patients diagnosed with CUD also receiving opioid substitution therapy are at risk for potential drug interactions. Therefore, a clinical monitoring of vigilance and respiratory function should be applied during inpatient treatment. Routine use of interaction check tools in patients diagnosed with CUD should also be considered by healthcare providers. In addition, therapeutic drug monitoring (TDM) should be used to increase medication safety in this patient population.

Drug use among individuals injured in non-fatal motor vehicle crashes and related policies in 2023

OBJECTIVE

Although driving-related policies aimed at mitigating drug-related motor vehicle crashes (MVCs) have been implemented in diverse communities, data regarding their effectiveness are largely absent. A comprehensive evaluation of these policies is necessary. Furthermore, as US states legalize the recreational use of cannabis, the impact of these policies on drug-related crashes also needs to be evaluated. The objective was to assess the association between drug use prevalence among individuals (age 16+) injured in non-fatal MVCs in 2023 and various related policies, including drug-impaired driving policies, sobriety checkpoints, enforcement programs, and state cannabis legalization status.

METHODS

We analyzed 2023 emergency medical services (EMS) records of individuals (age 16+) injured in non-fatal MVCs across 19  US states where EMS personnel indicated drug use, excluding duplicate, incomplete, and alcohol-only records. Using these counts, we calculated the prevalence of drug use among individuals (age 16+) injured in non-fatal MVCs in each state. The association between drug use prevalence and state-level policies, including drug-impaired driving laws (i.e., per se or zero tolerance), sobriety checkpoints, enforcement programs, and cannabis legalization laws, was evaluated using adjusted Poisson regression with random effects for state differences. Policies were assessed individually and in a full model to evaluate their individual and additive effects.

RESULTS

In 2023, 11,538 individuals (68.2% male) were injured in drug-related non-fatal crashes. Neither drug-impaired driving policies, the use of sobriety checkpoints, nor the implementation of State Judicial Outreach Liaisons influenced the prevalence of drug use among individuals injured in non-fatal crashes. In contrast, relative to states with no policy or cannabidiol/low tetrahydrocannabinol, those permitting recreational cannabis had significantly higher prevalence (adjusted prevalence ratio [aPR]: 1.57, 95% confidence interval [CI]: 1.22, 2.02). The implementation of sobriety checkpoints was associated with higher drug use prevalence (aPR: 1.59, 95% CI: 1.22, 2.09) when drug-impaired driving policies were absent, particularly in states permitting recreational cannabis.

CONCLUSION

Our findings show differences in drug use prevalence among individuals (age 16+) injured in non-fatal MVCs based on state-level policies, highlighting the need for holistic enforcement strategies to address drug-related crashes, especially amid the increasing risks associated with the legalization of recreational cannabis use.

Road hazard: a systematic review of traffic injuries following recreational cannabis legalization

PURPOSE

Acute cannabis use is associated with impaired driving performance and increased risk of motor vehicle crashes. Following the Canadian Cannabis Act's implementation, it is essential to understand how recreational cannabis legalization impacts traffic injuries, with a particular emphasis on Canadian emergency departments. This study aims to assess the impact of recreational cannabis legalization on traffic-related emergency department visits and hospitalizations in the broader context of North America.

METHODS

A systematic review was conducted according to best practices and reported using PRISMA 2020 guidelines. The protocol was registered on July 5, 2022 (PROSPERO CRD42022342126). MEDLINE(R) ALL (OvidSP), Embase (OvidSP), CINAHL (EBSCOHost), and Scopus were searched without language or date restrictions up to October 12, 2023. Studies were included if they examined cannabis-related traffic-injury emergency department visits and hospitalizations before and after recreational cannabis legalization. The risk of bias was assessed. Meta-analysis was not possible due to heterogeneity.

RESULTS

Seven studies were eligible for the analysis. All studies were conducted between 2019 and 2023 in Canada and the United States. We found mixed results regarding the impact of recreational cannabis legalization on emergency department visits for traffic injuries. Four of the studies included reported increases in traffic injuries after legalization, while the remaining three studies found no significant change. There was a moderate overall risk of bias among the studies included.

CONCLUSIONS

This systematic review highlights the complexity of assessing the impact of recreational cannabis legalization on traffic injuries. Our findings show a varied impact on emergency department visits and hospitalizations across North America. This underlines the importance of Canadian emergency physicians staying informed about regional cannabis policies. Training on identifying and treating cannabis-related impairments should be incorporated into standard protocols to enhance response effectiveness and patient safety in light of evolving cannabis legislation.

Risk of motor vehicle collision associated with cannabis and alcohol use among patients presenting for emergency care

BACKGROUND

The objective of this study was to examine the relationship between cannabis and alcohol use and occurrence of motor vehicle collision (MVC) among patients in the emergency department (ED).

METHODS

This was a cross-sectional study of visits to EDs in Denver, CO, Portland, OR, and Sacramento, CA by drivers who were involved in MVCs and presented with injuries (cases) and non-injured drivers (controls) who presented for medical care. We obtained blood samples and measured delta-9-THC and its metabolites. Alcohol levels were determined by breathalyzer or samples taken in the course of clinical care. Participants completed a research-assistant-administered interview consisting of questions about drug and alcohol use prior to their visit, context of use, and past-year drug and alcohol use. Multiple logistic regression was used to estimate the association between MVC and cannabis/alcohol use, adjusted for demographic characteristics. We then stratified participants based on levels of cannabis use and calculated the odds of MVC across these levels, first using self-report and then using blood levels for delta-9-THC in separate models. We conducted a case-crossover analysis, using 7-day look-back data to allow each participant to serve as their own control. Sensitivity analyses examined the influence of usual use patterns and driving in a closed (car, truck, van) versus open (motorcycle, motorbike, all-terrain vehicle) vehicle.

RESULTS

Cannabis alone was not associated with higher odds of MVC, while acute alcohol use alone, and combined use of alcohol and cannabis were both independently associated with higher odds of MVC. Stratifying by level of self-reported or measured cannabis use, higher levels were not associated with higher odds for MVC, with or without co-use of alcohol; in fact, high self-reported acute cannabis use was associated with lower odds of MVC (odds ratio [OR] 0.18, 95% confidence interval [CI] 0.05-0.65). In the case-crossover analysis, alcohol use alone or in combination with cannabis was associated with higher odds of MVC, while cannabis use alone was again associated with decreased odds of MVC.

CONCLUSIONS

Alcohol use alone or in conjunction with cannabis was consistently associated with higer odds for MVC. However, the relationship between measured levels of cannabis and MVC was not as clear. Emphasis on actual driving behaviors and clinical signs of intoxication to determine driving under the influence has the strongest rationale.

Effects of cannabis legalization on the use of cannabis and other substances

PURPOSE OF REVIEW

As more jurisdictions legalize cannabis for non-medical use, the evidence on how legalization policies affect cannabis use and the use of other substances remains inconclusive and contradictory. This review aims to summarize recent research findings on the impact of recreational cannabis legalization (RCL) on cannabis and other substance use among different population groups, such as youth and adults.

RECENT FINDINGS

Recent literature reports mixed findings regarding changes in the prevalence of cannabis use after the adoption of RCL. Most studies found no significant association between RCL and changes in cannabis use among youth in European countries, Uruguay, the US, and Canada. However, some studies have reported increases in cannabis use among youth and adults in the US and Canada, although these increases seem to predate RCL. Additionally, there has been a marked increase in unintentional pediatric ingestion of cannabis edibles postlegalization, and an association between RCL and increased alcohol, vaping, and e-cigarette use among adolescents and young adults.

SUMMARY

Overall, the effects of cannabis legalization on cannabis use appear to be mixed. Further monitoring and evaluation research is needed to provide longer-term evidence and a more comprehensive understanding of the effects of RCL.

Increased identification of cannabis use among drivers involved in motor vehicle collisions using an expanded cannabis inventory

OBJECTIVES

The objectives of this study were to implement and examine the potential capture rate of a novel instrument, the Expanded Cannabis Inventory, in a population of emergency department (ED) patients presenting after motor vehicle collisions (MVC).

METHODS

Study participants who presented to the ED after MVC were recruited from three hospitals in cannabis-legal states (Denver, CO; Portland, OR; and Sacramento, CA). Research assistants (RAs) administered the Expanded Cannabis Inventory, which includes a wide variety of products that have become readily available in states where cannabis is legal, in addition to assessments related to patient demographic characteristics, general health, cannabis attitudes, and dependency measures. RAs also obtained blood samples for delta-9-THC and metabolites.

RESULTS

Among 692 participants who provided responses to questions about cannabis use, 292 (42%) reported past-year use. Seventy-eight (27%) of those identified as using cannabis were only captured due to items in the expanded instrument. These patients were more likely to be White and were more likely to perceive daily use to be of high risk. Fewer had Cannabis Use Disorder Inventory Test (CUDIT) scores consistent with hazardous cannabis use. However, more of the patients only captured by the expanded instrument had high measured blood levels of delta-9-THC on samples obtained in the ED.

CONCLUSIONS

Changing cannabis use patterns must be reflected in our measurements for clinical practice, research, and surveillance. Instruments that are the current standard in clinical practice capture limited data and may no longer perform well enough to identify a complete cohort or to provide insight into the health behaviors of patients.